SUMMARY
with renal hypertension. Their ages ranged from 16 to 69 years. They were all hospitalized, and the hemodynamic study was performed in the fasting state. Cardiac output was measured by the dye dilution technique using indocyanine green. Total peripheral resistance and left ventricular work were determined by the calculation.
2. Clinical studies Bay-a 1040 was administered to 20 hypertensive patients in divided dosage (2 to 4 times daily). The daily dose of the drug, ranging from 10 to 60mg., was determined from the response curve of the blood pressure to a single oral administration. The dose was gradually increased until adequate lowering of blood pressure was achieved or until a intolerable side effect appeared. Any patient was observed without Bay-a 1040 for at least 1 month as the control period before the administration of the drug. If other antihypertensive agents were given before the administration of Bay-a 1040, the administration of these agents was continued throughout the study.
RESULTS

Hemodynamic effects
Acute effects on heart rate and blood pressure: The highest increase of heart rate occurred 30min. after the administration of the drug, with the average increase of 17 percent. The increased heart rate remained elevated for 180min. (Fig. 1 ). Systolic and diastolic pressure quickly fell in all patients. The average systolic pressure reduction was 21.2 percent (from 171.1 to 134.8 mm.Hg) (p<0.05) 180min. after drug administration, the average diastolic pressure reduction being 20 percent (p<0.05) (Fig. 2) . Jap. Heart J. March, 1972 The greatest response was observed in a case of renal failure, whereas the duration of the response was short (for about 1 hour).
Hemodynamic studies were performed 180min. after oral administration of 10mg. of Bay-a 1040 in other 7 patients, including 4 patients who had been given the drug previously.
Effects on heart rate and blood pressure ( Fig. 3 ): Heart rate increased in 3 patients who had not received the drug, while it decreased in 4 patients who had been treated by the drug. The average systolic pressure reduction was 44.6mm.Hg (p<0.05), the average diastolic pressure reduction being 19.1 mm.Hg (p<0.05). The average mean pressure reduction was 27.6mm.Hg (p<0.05).
Effects on cardiac output and stroke volume ( Effects on total peripheral resistance ( Fig. 4) : Total peripheral resistance fell in all patients averaging 899.7dyne. sec. cm.-5 (p<0.05).
In particular, 1 case of malignant hypertension showed a marked decrease of 2,303dyne. sec. Effects on left ventricular work (Fig. 4) : Left ventricular work increased in 3 of 7 cases, but decreased slightly in 4 cases, resulting in an average increase of 2.07Kg. M.
Clinical efficacy
The following cases are presented as typical ones. Case 1 (Fig. 5) . A 78-year-old female, essential hypertension: She received a daily dose of 60mg. of deserpidine. A greater antihypertensive effect was noted when Bay-a 1040 was added in a dose of 30mg. per day. The systolic pressure decreased by 30mm.Hg and the diastolic pressure by 15mm.Hg. When the drug was discontinued, the systolic and diastolic pressure returned to the levels observed in the period prior to the administra- Of the 20 patients treated, a significant systolic reduction more than 30mm.Hg was obtained in 9, while a significant diastolic reduction more than 20mm.Hg was obtained in 4. Three patients became normotensive. Changes in heart rate during the treatment with the drug were variable, and the result was not significant.
During the treatment, burning sensation of face and limbs was noted in one case. In another case, head cloudiness and dryness of the mouth were complained of. These side effects, however, were mild and not significant. J ap. Heart J. March, 1972 
DISCUSSION
A single oral administration of 10mg. of Bay-a 1040 produced a moderate reduction of systolic and diastolic arterial pressures in a group of 6 hypertensive patients. The decrease in blood pressure was accompanied by an increase in cardiac output and a significant and consistent decrease in total peripheral resistance. Heart rate showed a tendency to increase after a single oral administration and a tendency to decrease during its treatment. Changes in left ventricular work were variable.
Grollman et al. reported that in hypertensive rats antihypertensive effect of Bay-a 1040 occurred 1 to 2 hours after the oral administration and blood pressure returned to control levels by 24 hours. Stoepel noted that oral administration of Bay-a 1040 in dogs resulted in a transient rise in cardiac output and stroke volume and a decrease in the total peripheral resistance. These findings are consistent with our data.
Based on these observations, it seems reasonable to postulate that the antihypertensive effect of Bay-a 1040 is due to the primary reduction of vascular tone. However, the mechanism of its reduction awaits further investigations.
In hypertensive patients treated with Bay-a 1040 in doses of 10 to 60mg.
per day, a significant antihypertensive effect was achieved. Of the 20 patients treated, 13 obtained a systolic arterial pressure reduction of more than 20mm.Hg and 12 a diastolic pressure reduction of more than 10mm.Hg. It is of particular importance that a marked antihypertensive effect was observed in cases of malignant hypertension, renovascular hypertension and uremia which showed a marked resistance to other antihypertensive agents. In these cases, however, the antihypertensive effect was of shorter duration (Table I) .
Because of its antihypertensive action and relative freedom from toxicity, Bay-a 1040 should be a useful addition to the list of drugs available for the treatment of essential hypertension, renovascular hypertension and malignant hypertension. Additional data are needed, however, to determine the potential benefits of combining Bay-a 1040 with other antihypertensive drugs. Finally, the problem of tolerance and side-effects will have to be evaluated by more prolonged investigation.
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